The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical utility of repeat next-generation sequencing in patients with driver-negative non-small cell lung cancer: A report from the LC-SCRUM-TRY screening platform.
 
Hiroki Izumi
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly; Merck; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Lilly; Novartis
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Shuji Murakami
No Relationships to Disclose
 
Shoichi Ishikawa
No Relationships to Disclose
 
Shoichiro Yamamoto
Speakers' Bureau - Asahi Kasei; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Kyorin; Kyowa Kirin Pharmaceutical Development; Taiho Pharmaceutical; Takeda
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novar Pharma; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer Pharma Japan. (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Delta-Fly Pharma (Inst); EPS Corporation (Inst); Fortrea Japan (Inst); Gilead Sciences (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel International Inc (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Kenichi Chikamori
Honoraria - AstraZeneca; Chugai Pharma; Lilly Japan; Nippon Kayaku; Ono Yakuhin; Pfizer; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Takeda
 
Mayu Kawakami
No Relationships to Disclose
 
Hiromi Watanabe
Speakers' Bureau - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
 
Saori Takata
No Relationships to Disclose
 
Jun Sakakibara-Konishi
No Relationships to Disclose
 
Tomohiro Kato
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Merck Sharp & Dohme; Nippon Kayaku; Ono Pharmaceutical
 
Hirokazu Toge
No Relationships to Disclose
 
Jun Sugisaka
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin International; MSD
 
Masahide Mori
Speakers' Bureau - Abbvie; Astrazeneca; Boehringer Ingelheim; Chugai Pharma; Daiici-Sankyo; Kyowa-kirin; Lilly; MSD; Nihonkayaku; Novartis; Ono pharmacoceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst)
 
Haruko Daga
Honoraria - AstraZeneca
 
Shuichi Asano
No Relationships to Disclose
 
Kiyotaka Yoh
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; GlaxoSmithKline
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Janssen; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Other Relationship - AstraZeneca
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; ArriVent Biopharma, Inc.; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Janssen; Lilly Japan; Merck; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amplity, Inc.; ArriVent Biopharma, Inc.; Bayer HealthCare Pharmaceuticals Inc.,; Boehringer Ingelheim; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Guardant Health Japan Corp.; Haihe Biopharma Co., Ltd.; iTeos Therapeutics Inc.; Lilly Japan; Nippon Boehringer Ingelheim; Novartis; Pfizer; Pharma Mar, S.A.; Taiho Pharmaceutical
Research Funding - AbbVie Inc., (Inst); AccuraGen Inc. (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); ArriVent Biopharma, Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); BillionToOne, Inc. (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merus (Inst); MSD K.K. (Inst); Nippon Kayaku (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)